CRISPR-Cas9 KO of ARID1A in ID8 cells investigated in both an intraperitoneal and an orthotopic model showed increased tumour-infiltrating lymphocytes and PD-L1 levels and a greater response to an anti-PD-L1 antibody compared to WT ARID1A tumours, with lower tumour burden and prolonged survival [174]. This evidence concerns the gene ARID1A and neoplasm.